Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 25

Results For "Life-Science"

668 News Found

Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
News | August 08, 2025

Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr

Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025


Bio-Rad names Rajat Mehta as EVP - Global Commercial Operations
People | August 01, 2025

Bio-Rad names Rajat Mehta as EVP - Global Commercial Operations

Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics


Bristol Myers Squibb and Bain Capital launch biotech company NewCo
News | July 31, 2025

Bristol Myers Squibb and Bain Capital launch biotech company NewCo

NewCo’s pipeline includes five investigational medicines


Wallace Pharmaceuticals appoints Chinmaya Mohanty as VP & Head – Human Resources
People | July 30, 2025

Wallace Pharmaceuticals appoints Chinmaya Mohanty as VP & Head – Human Resources

He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt


Syngene International appoints Gaurav Kushwaha as CTO
People | July 28, 2025

Syngene International appoints Gaurav Kushwaha as CTO

Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited


Granules India CEO K V Sitaram Rao resigns
People | July 27, 2025

Granules India CEO K V Sitaram Rao resigns

Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service


Biogen to invest $2 billion to expand manufacturing capability in North Carolina
News | July 21, 2025

Biogen to invest $2 billion to expand manufacturing capability in North Carolina

Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date


Waters, BD biosciences unit agree to $17.5 billion merger
News | July 16, 2025

Waters, BD biosciences unit agree to $17.5 billion merger

The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026